# Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma

> **NCT07099547** · PHASE2 · RECRUITING · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 60 (estimated)

## Conditions studied

- Biliary Tract Carcinoma

## Interventions

- **DRUG:** ZG005
- **DRUG:** Tislelizumab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT07099547
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-02
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07099547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07099547, "Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07099547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*